Balaji Amines presents Q2 FY27 investor presentation

Balaji Amines Limited has officially submitted its Investor Presentation for the second quarter and first half of fiscal year 2027 (Q2 & H1 FY27). The presentation details the company’s financial performance, highlighting a significant year-on-year revenue growth of 36% to ₹472 crore for Q2 FY27. EBITDA rose by 58% to ₹106 crore, and Profit After Tax (PAT) increased by 82% to ₹67 crore. For H1 FY27, consolidated PAT nearly doubled to ₹146 crore.

Investor Presentation for Q2 & H1 FY27 Released

Balaji Amines Limited has formally submitted its Investor Presentation for the financial results of the second quarter (Q2) and the first half (H1) of the fiscal year 2027 (FY27). This comprehensive document provides stakeholders with detailed insights into the company’s operational and financial performance during the specified periods.

Key Financial Highlights

The presentation underscores a robust financial performance for Q2 FY27. On a consolidated basis, Total Revenue experienced a substantial year-on-year growth of 36%, reaching ₹472 crore. EBITDA saw a significant increase of 58%, amounting to ₹106 crore, with a healthy margin of 22%. Furthermore, Profit After Tax (PAT) surged by 82% to ₹67 crore.

For the first half of FY27 (H1 FY27), the company’s consolidated PAT nearly doubled, reaching ₹146 crore.

Operational Progress and Future Outlook

Despite external challenges such as raw material availability and supply chain disruptions, Balaji Amines maintained revenue resilience through its stable product portfolio. Standalone volumes saw an improvement of 11% over the previous quarter (Q1 FY27). The company has commenced commercial production at its upgraded Acetonitrile facility and is actively building its DME customer network following PESO approval for DME road tanker valves.

Looking ahead, N-Methyl Morpholine is slated for commercialization. Expansion projects at BSCL’s Unit-I are on track for commissioning by the end of FY27, and the Unit-II HCN, NaCN, and EDTA project is targeted for Q4 FY27. The company expresses confidence in driving sustainable growth and long-term shareholder value through its visible expansion roadmap and disciplined execution.

Accessing the Presentation

The Investor Presentation is also available for access on the company’s official website at https://www.balajiamines.com/investor-relations.php.

Source: BSE

Previous Article

Zydus Lifesciences reports Q2 FY27 financial results

Next Article

Cera Sanitaryware approves Q2 FY27 unaudited results and director re-appointments